NCT05674526 - A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

June 1, 2026

Conditions

Colorectal Cancer MetastaticSquamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL

WU-NK-101 - Dose Escalation

WU-NK-101 administered on Days 1, 15, 30 and 44

DRUG

Cetuximab - Dose Escalation

Cetuximab 500mg/m2 administered on Days 29 and 43

BIOLOGICAL

WU-NK-101 - Cohort Expansion

WU-NK-101 administered on Days 2 and 16

BIOLOGICAL

Cetuximab - Cohort Expansion

Cetuximab 500mg/m2 administered on Days 1 and 15

Trial Locations (2)

Montefiore Medical Center, The Bronx

UCSF, San Francisco

All Listed Sponsors

lead

Wugen, Inc.

INDUSTRY